Pharmaceutical services provider PCI Pharma Services will be at CPhI Worldwide, reinforcing its reputation for providing the global healthcare industry with excellence in service delivery
An ongoing strategic investment and expansion programme has enabled PCI to build its market-leading position enabling drug development solutions from molecule to market that deliver true speed to market and commercial success for clients across the world.
Earlier this month, PCI announced its focus on further European growth with the acquisition of Dublin-based pharmaceutical and healthcare contract packaging services provider, Millmount Healthcare.
With headquarters in Philadelphia, PCI’s global reach is balanced with local focus through its operations in North America and Europe, supporting medicines destined to reach more than 100 countries around the world.
Most recently, PCI has aligned its business unit operations under new brand identities — the organisation will continue to operate under the core ‘PCI Pharma Services’ name, with sub-branding introduced relevant to distinct areas of the business:
Bill Mitchell, President and CEO at PCI, said: “We strive to position PCI to best support our clients in bringing new medicines to successful commercialisation. Our continued investment to expand our specialist service offerings mean we are able to provide clients with a full service from early stage development and manufacturing, through the clinical stages and ultimately commercial launch including serialisation.”
“As all elements of the service operate within one company, we are able to ensure a seamless transition as products move through the cycle of development to commercial launch. The introduction of sub-brands provides clarity for our clients on the nature of our service offer, while maintaining overall brand confidence.”
“Since 2012, the business has gone through significant change focusing on strategic investments, acquisitions and expansion to deliver a strategy developed to best support our client needs with a model of industry-leading expertise, world-class facilities and cutting-edge technologies. This unique blend enables us to build effective and long-term partnerships truly adding value to our clients.”
PCI features cGMP manufacturing, laboratory, packaging, storage and distribution facilities across the two continents audited by both the MHRA and FDA, as well as major regulatory bodies in Europe, North America, South America and the Asia Pacific region.
With an exemplary regulatory record and export experience, PCI’s highly trained associates serve as trusted partners to its customers, dedicated to ensuring outstanding quality and care throughout all stages of the relationship.
The recent acquisition of Millmount Healthcare further strengthens PCI’s European footprint and specialist packaging capabilities.
Meet PCI at CPhI WW 2017: hall 4, booth F30